Clinical Trial Update: Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of OC000459 in asthmatic subjects completed; results not detailed in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• OC000459

Snippet

Sponsor: Oxagen Ltd | Conditions: Asthma | Phase 2 | Status: COMPLETED